Sabby Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Sabby Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-457	Closed	-$752K	–	192
2017 Q2	$752K	Buy	457 +82	+22%	+$1.27K	0.05%	114
2017 Q1	$538K	Buy	375 +254	+210%	+$3.77K	0.03%	175
2016 Q4	$167K	Sell	121 -479	-80%	-$7.68K	0.01%	250
2016 Q3	$1.08M	Sell	600 -379	-39%	-$6.1K	0.04%	175
2016 Q2	$1.41M	Buy	+979	New	+$13.3K	0.07%	134
2015 Q4	–	Sell	-260	Closed	-$279K	–	348
2015 Q3	$279K	Buy	+260	New	+$2.84K	0.01%	328

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UIM

USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sabby Management's LXRX Position: Q2 2017 in Review

Sabby Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 28,626 shares — an estimated $443K sold.

Sabby Management first reported a position in LXRX in Q4 2013 and held it in 8 quarters. The position peaked at $5.07M in Q1 2015. 136 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

Sabby Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 28,626 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $443K.
Sabby Management first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Sabby Management's Lexicon Pharmaceuticals position peaked at $5.07M in Q1 2015.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.